Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 331 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Locations: - Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria — Peoria, Arizona
- Arizona Center for Cancer Care - Biltmore — Phoenix, Arizona
+ 197 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Locations: - University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Fremont - Rideout Cancer Center — Marysville, California
- VA Palo Alto Health Care System — Palo Alto, California
+ 197 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Locations: - Research Site — Birmingham, Alabama
- Research Site — Mobile, Alabama
- Research Site — Anchorage, Alaska
+ 89 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …
Sponsor: NRG Oncology
NCT ID: NCT07441681
Locations: - Tower Cancer Research Foundation — Beverly Hills, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
+ 60 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Locations: - Ironwood Cancer and Research Center — Chandler, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
- Providence St Jude Medical Center — Fullerton, California
+ 46 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Locations: - University of Alabama- Birmingham ( Site 5015) — Birmingham, Alabama
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037) — Irvine, California
- University of California Irvine Medical Center ( Site 6006) — Orange, California
+ 26 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Locations: - Helios CR Inc./RadNet — Cerritos, California
- City of Hope National Cancer Center — Duarte, California
- Hoag Memorial Hospital — Irvine, California
+ 13 more sites in the U.S.
Phase 3 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…
Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Locations: - Mayo Clinic Hospital — Phoenix, Arizona
- Providence Medical Foundation — Fullerton, California
- Univ of California Irvine College of Medicine — Orange, California
+ 10 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…
Sponsor: Privo Technologies
NCT ID: NCT05893888
Locations: - City of Hope National Medical Center — Duarte, California
- Miami Cancer Institute — Miami, Florida
- The University of Chicago — Chicago, Illinois
+ 1 more site in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…
Sponsor: Mayo Clinic
NCT ID: NCT06915727
Locations: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
The goal of this study is to determine whether fractionated Stereotactic radiosurgery (SRS) for spine metastases is associated with improved local tumor control compared to single-fraction SRS. Patients will be randomized to treatment with…
Sponsor: Stanford University
NCT ID: NCT06173401
Locations: - Stanford University School of Medicine — Palo Alto, California